AGC adds another major Covid-19 vaccine maker to the client list with BioNTech pact for plasmid DNA
With the demand for contract manufacturers at an all-time high amid Covid-19, German firm AGC hasn’t been shy about its open-door policy with major players. Now, the CDMO will work with BioNTech to produce plasmid DNA crucial to its vaccine.
“The team at Heidelberg is enthusiastically embracing this important project with BioNTech,” general manager Dieter Kramer said in a press release. “Every team member has a deep sense of pride in our COVID-19 teams and we look forward to supporting BioNTech in the production of their mRNA-based COVID-19 vaccine with Plasmid DNA.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.